HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19082488
Knihovny.cz E-resources
- MeSH
- CD4-Positive T-Lymphocytes immunology MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Cytotoxicity Tests, Immunologic MeSH
- Neoplasms, Experimental immunology therapy virology MeSH
- Genetic Therapy MeSH
- Ifosfamide analogs & derivatives therapeutic use MeSH
- Immunoenzyme Techniques MeSH
- Immunotherapy MeSH
- Papillomavirus Infections immunology therapy virology MeSH
- Angiogenesis Inhibitors therapeutic use MeSH
- Interleukin-12 physiology MeSH
- Humans MeSH
- Human papillomavirus 16 pathogenicity MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Tumor Cells, Cultured MeSH
- Cell Proliferation * MeSH
- Flow Cytometry MeSH
- Lymphocytes, Tumor-Infiltrating immunology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- chlorobromofosfamide MeSH Browser
- Ifosfamide MeSH
- Angiogenesis Inhibitors MeSH
- Interleukin-12 MeSH
We have examined the effect of IL-12-producing cellular vaccines on the cytotoxicity and proliferative potential of CD45+ tumour-infiltrating cells (TIL) in mice carrying syngeneic TC-1 and TC-1/A9 HPV 16-associated tumours after chemotherapy with CBM-4A ifosfamide derivative. The chemotherapy resulted in the decrease of the CD4+ and CD8+ TIL, increase of the Gr-1+/CD11b+ TIL, no changes in the infiltration with CD4+/CD25+ Treg TIL, and decrease of the cytolytic and proliferative potential of the CD45+ TIL. Subsequent immunotherapy with the IL-12-producing, genetically modified TC-1 (TC-1-IL-12) cells increased tumour infiltration with CD8+ and CD4+ cells, decreased the Gr-1+/CD11b+ cells, and increased the cytolytic and proliferative potential of the CD45+ TIL. Taken together, these findings suggest that peritumoral administration of the IL-12-producing cellular vaccine can restore the cytolytic potential and inhibit immunosuppressive TIL-dependent mechanisms in the individuals bearing HPV 16-associated tumours, and explain our previously described tumour-inhibitory effects of the vaccine in mice with minimal residual disease after the tumour chemotherapy.
